Natera, INC Form 4 insider transactions

Natera, Inc. Director Gail Boxer Marcus executed a pre-planned sale of 4,000 shares of common stock totaling approximately $650,000 on June 10, 2025, pursuant to a Rule 10b5-1 trading plan.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 3,000 shares of common stock on June 2, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Natera, Inc. CEO and President Steven Leonard Chapman sold a total of 6,111 shares of common stock on June 2, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Jonathan Sheena, co-founder of Natera, Inc., sold shares of common stock on May 9 and May 12, 2025, under pre-arranged Rule 10b5-1 trading plans.

Natera's CEO, Steven Leonard Chapman, sold a portion of his common stock holdings on May 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., executed multiple sales of common stock on May 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Director Marcus Gail Boxer reported the sale of Natera, Inc. (NTRA) common stock on May 1, 2025, according to a Form 4 filing with the SEC.

Jonathan Sheena, co-founder of Natera, Inc., sold 439 shares of common stock on April 28, 2025, to satisfy tax withholding obligations related to vesting RSUs.

Matthew Rabinowitz, Executive Chairman of Natera, Inc., sold 1,718 shares of common stock on April 28, 2025, to satisfy tax withholding obligations related to vesting RSUs.

Daniel Rabinowitz, SEC and Chief Legal Officer of Natera, Inc., reports the sale of 1,993 shares of common stock to cover tax obligations related to RSU vesting.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 2,206 shares of common stock on April 28, 2025, to cover tax obligations related to vesting RSUs.

John Fesko, President and Chief Business Officer of Natera, Inc., sold 1,709 shares of common stock on April 28, 2025, to satisfy tax withholding obligations related to vesting RSUs.

Natera's CEO, Steven Chapman, sold 6,203 shares of common stock on April 28, 2025, to satisfy tax withholding obligations related to vesting RSUs.

Natera's CFO, Michael Brophy, sold shares of common stock to cover tax obligations related to vesting RSUs and under a pre-arranged 10b5-1 trading plan.

Director Herm Rosenman acquired 164 shares of Natera, Inc. common stock through the issuance of fully vested Restricted Stock Units (RSUs) in lieu of quarterly retainer fees.

Director James Healy of Natera, Inc. receives fully vested restricted stock units (RSUs) in lieu of quarterly retainer fees.

Director Roelof Botha acquired 185 shares of Natera, Inc. common stock through the issuance of RSUs in lieu of quarterly retainer fees.

Director Roy D. Baynes acquired 116 shares of Natera, Inc. common stock through fully vested Restricted Stock Units (RSUs) in lieu of quarterly retainer fees.

Natera's CFO, Michael Brophy, reported the sale of common stock and vesting of restricted stock units (RSUs) in a series of transactions from April 22 to April 24, 2025, according to a Form 4 filing with the SEC.

Michael Brophy, CFO of Natera, Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Natera's CEO, Steven Chapman, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

John Fesko, President and Chief Business Officer of Natera, Inc., sold shares of common stock on April 21, 2025, to satisfy tax withholding obligations related to vesting RSUs.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold shares to cover tax withholding obligations related to vesting RSUs.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., reports the vesting of Restricted Stock Units and subsequent sale of shares to cover tax obligations.

Jonathan Sheena, co-founder of Natera, Inc., reports transactions involving common stock and restricted stock units, including sales to cover tax obligations.

Jonathan Sheena, co-founder of Natera, Inc., sold shares of common stock on April 3rd and 4th, 2025, under pre-arranged Rule 10b5-1 trading plans.

Director Marcus Gail Boxer reports exercising stock options and selling Natera (NTRA) shares on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold a portion of his holdings in Natera common stock on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Michael Brophy, CFO of Natera, Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Natera's CEO, Steven Chapman, reports the vesting of restricted stock units and subsequent sales of common stock to cover tax obligations and under a pre-arranged trading plan.